By combining previously developed multiplex EGFR assays [22, 27], as well as adding other EGFR mutations relevant to NSCLC patient monitoring, we developed an assay capable of detecting 5 sensitizing mutations (p.L858R, p.L861Q, p.G719S, p.G719A, p.G719C), 12 different delins in exon 19, and 2 resistance mutations (p.T790M and p.C797S) in a single reaction. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.